Effects of perindopril on cardiovascular outcomes in hypertension clinical trials: traditional and network meta-analyses

CI 1⁄4 confidence interval; CV 1⁄4 cardiovascular; CHD 1⁄4 coronary heart disease; MACE 1⁄4 major adverse CV events (stroke, CHD, CV death; estimated for some trials); HF 1⁄4 heart failure. These data suggest that, in clinical trials, amlodipine significantly increased the risk of heart failure, but prevented other cardiovascular endpoints at least as well as other regimens, including those that started with a diuretic.